Dupixent® ( dupilumab ) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP )
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled ...
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
5 %
|
|
META
|
Neutral
|
1 %
|
|
SNY
|
Neutral
|
13 %
|
